{
  "id": "dopamine-agonist",
  "title": "Dopamine agonist",
  "lang": "en",
  "source_lang": "en",
  "summary": "A dopamine agonist activates dopamine receptors and is used chiefly in Parkinson’s disease, prolactin disorders, and selected other conditions.",
  "category": "health",
  "subcategory": "drugs",
  "type": "concept",
  "aliases": [
    "Dopamine receptor agonist",
    "Dopaminergic agonist"
  ],
  "generated_at": "2026-11-05",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/dopamine-agonist/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/dopamine-agonist/",
      "json": "https://aiwiki.page/zh/dopamine-agonist.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "A dopamine agonist is a substance that binds to and activates a dopamine receptor, reproducing some of the signaling effects of dopamine. In clinical medicine, the term usually refers to drugs that act directly at these receptors rather than increasing dopamine synthesis or preventing its breakdown. Their effects depend on the receptor subtypes activated, the tissues reached, and the duration of exposure.\n\nDopamine agonists have important roles in treating Parkinson’s disease and disorders caused by excessive prolactin secretion. Some are also used for restless legs syndrome, while particular agents have vascular or metabolic indications. These applications reflect dopamine’s diverse functions in movement, motivation, endocrine regulation, and circulation. The drugs are not interchangeable: their therapeutic effects and adverse reactions differ substantially according to receptor selectivity, chemical structure, and delivery method."
    },
    {
      "heading": "Receptor pharmacology and biological mechanisms",
      "text": "Dopamine receptors belong to the G protein–coupled receptor family. Five subtypes are conventionally divided into two groups: D1-like receptors, comprising D1 and D5, and D2-like receptors, comprising D2, D3, and D4. D1-like receptors generally couple to signaling proteins that increase adenylyl cyclase activity and intracellular cyclic AMP. D2-like receptors generally inhibit this pathway and also influence potassium channels, calcium channels, and other signaling systems. These descriptions summarize major pathways rather than every cellular response; receptor effects vary with cell type and signaling context.\n\nMost established dopamine agonists used in Parkinson’s disease or prolactin disorders act predominantly at D2-like receptors. Their affinity for D3 receptors varies considerably. Pramipexole, for example, has a preference for D3 over D2 receptors in laboratory binding studies. Such differences help explain pharmacological variation, but a binding-affinity measurement alone does not predict clinical efficacy or an individual adverse reaction. Receptor occupancy, intrinsic efficacy, active metabolites, and drug concentrations in different tissues also matter.\n\nIn the basal ganglia, dopamine helps regulate interconnected pathways controlling movement. Parkinson’s disease involves degeneration of dopamine-producing neurons in the substantia nigra and loss of their projections to the striatum. Dopamine agonists stimulate receptors within this system without requiring conversion into dopamine by the surviving neurons. They can therefore improve movement despite substantial presynaptic neuronal loss, although their effects still depend on the condition of postsynaptic receptors and wider neural circuits.\n\nEndocrine effects arise through a different anatomical arrangement. Dopamine released by neurons of the hypothalamus reaches the anterior pituitary gland through the hypophyseal portal circulation. It tonically inhibits prolactin release by activating D2 receptors on lactotroph cells. Agonists acting at these receptors suppress secretion and can reduce the size of prolactin-secreting pituitary tumors. Other actions, including effects on nausea, blood pressure, and behavior, arise from stimulation of receptors outside the motor circuits targeted in Parkinson’s disease.\n\nThe distinction between a full and a partial agonist is also important. A full agonist can produce the maximum response available in a particular experimental system, whereas a partial agonist produces a lower maximum under comparable conditions. Some antipsychotic drugs are D2 partial agonists but have a different clinical role from conventional antiparkinsonian dopamine agonists. In the presence of substantial endogenous dopamine, partial agonists may reduce net receptor signaling by competing with the stronger agonist. Thus, the label “dopamine agonist” describes receptor activity, not a single therapeutic effect."
    },
    {
      "heading": "Principal drugs and chemical classes",
      "text": "A traditional classification separates ergot-derived from non-ergot dopamine agonists. This distinction has practical significance because some ergot-derived compounds also activate serotonin receptors associated with fibrotic complications. Chemical class nevertheless does not fully determine receptor selectivity or safety: individual agents require separate consideration.\n\nBromocriptine and cabergoline are ergot-derived agonists used especially in disorders of prolactin secretion. Bromocriptine has a relatively shorter duration of action and has also been used in Parkinson’s disease and acromegaly. Cabergoline acts for much longer and can be administered infrequently in endocrine treatment. Pergolide was formerly used for Parkinson’s disease but was withdrawn from the United States market in 2007 following evidence of cardiac valve injury. Its history illustrates how adverse effects recognized after widespread use can alter the clinical position of an entire drug class.\n\nThe principal non-ergot agents used for Parkinson’s disease include pramipexole, ropinirole, and rotigotine. Pramipexole and ropinirole are available in oral formulations, including extended-release products in many jurisdictions. Rotigotine is delivered through a transdermal patch, producing sustained systemic exposure over the application period. These drugs chiefly target D2-like receptors, although their complete receptor profiles differ. Piribedil, available in some countries, combines dopaminergic actions with effects at adrenergic receptors.\n\nApomorphine is another non-ergot agonist, with activity at both D1-like and D2-like receptors. Despite its name and historical chemical relationship to morphine, its therapeutic action is dopaminergic rather than that of a conventional opioid analgesic. Its extensive first-pass metabolism makes ordinary oral administration unsuitable. Subcutaneous injection and continuous infusion are established delivery approaches; availability of other formulations differs between countries and over time.\n\nOther agents illustrate the breadth of the category. Quinagolide is a non-ergot D2 agonist used for hyperprolactinemia in some jurisdictions. Fenoldopam is a predominantly D1-receptor agonist administered intravenously for short-term management of severe hypertension in settings where it is licensed. Its vascular actions distinguish it from the centrally acting drugs used for movement disorders. Dopamine itself also activates dopamine receptors, but intravenous dopamine has concentration-dependent effects at adrenergic receptors and is generally discussed separately as a vasoactive catecholamine.\n\nThe relevant classification therefore depends on the question being asked. Chemical structure is useful when considering ergot-associated fibrosis; receptor selectivity is central to mechanism; and formulation is crucial when comparing rapid rescue treatment with sustained symptom control. Grouping all these drugs simply as “dopaminergic” can conceal clinically important differences."
    },
    {
      "heading": "Absorption, distribution, metabolism, and delivery",
      "text": "Differences in pharmacokinetics explain much of the variation between dopamine agonists. Drugs intended to treat Parkinson’s disease must achieve effective concentrations beyond the blood–brain barrier. By contrast, prolactin suppression depends on access to anterior pituitary lactotrophs, whose vascular environment differs from that of most brain tissue. Peripheral effects can occur alongside either therapeutic action, particularly in the gastrointestinal and cardiovascular systems.\n\nPramipexole is eliminated largely unchanged through the kidneys. Its exposure therefore increases when renal clearance is reduced. Ropinirole is metabolized principally through the hepatic enzyme CYP1A2, so factors affecting this pathway can alter its concentration. Cigarette smoking induces CYP1A2 activity, while certain interacting medicines inhibit it. These contrasting elimination routes are one reason why two drugs with broadly similar receptor actions can behave differently in the same patient.\n\nDuration of action also varies markedly. Immediate-release pramipexole and ropinirole generally require repeated administration to maintain clinical coverage, whereas extended-release formulations prolong absorption. Cabergoline has a terminal elimination half-life measured in days, commonly around 60–100 hours depending on the population and method of measurement. Its prolonged action supports widely spaced endocrine dosing, but also means that effects and interactions do not disappear immediately after the final dose.\n\nRotigotine bypasses gastrointestinal absorption through transdermal delivery. This can be relevant when swallowing, gastric emptying, or timing of oral medication complicates treatment. The patch does not eliminate systemic adverse effects and introduces local problems such as application-site reactions. Similarly, continuous subcutaneous apomorphine infusion can reduce fluctuations associated with intermittent dosing, but requires a delivery device and may cause nodules or irritation at infusion sites. Delivery technology changes the exposure pattern, not the underlying receptor mechanism.\n\nApomorphine injection has a rapid onset and relatively short duration, making it suitable for selected Parkinsonian “off” episodes. Continuous infusion instead aims to maintain exposure over an extended period. These are pharmacologically distinct uses of the same molecule: one seeks a rapid transition from reduced mobility to improved movement, while the other seeks fewer interruptions in motor control.\n\nThere is no single universally valid dose-equivalence scale across all agonists and indications. Levodopa-equivalent daily dose calculations are used in Parkinson’s research and clinical descriptions, but they are approximate conversions developed for particular purposes. They do not establish equivalent risks of hallucinations, impulse-control disorders, endocrine suppression, or withdrawal. Comparisons of drugs consequently require attention to both pharmacodynamics and exposure rather than milligram dose alone."
    },
    {
      "heading": "Role in Parkinson’s disease",
      "text": "Dopamine agonists improve several motor manifestations of Parkinson’s disease, including slowness of movement, rigidity, and, in some patients, tremor. They can be used as initial treatment or combined with levodopa, the metabolic precursor of dopamine. Levodopa usually produces a larger improvement in motor symptoms, while dopamine agonists offer a different balance of symptom control, duration of action, and adverse effects.\n\nIn early disease, trials comparing an agonist-first approach with a levodopa-first approach have generally found fewer early motor complications such as dyskinesia in the agonist-first groups. However, these groups often have less motor improvement and more adverse effects such as sleepiness, hallucinations, and peripheral edema. Many participants initially receiving an agonist subsequently require levodopa. The findings therefore concern treatment strategies and timing, not proof that agonists prevent the underlying disease process.\n\nIn established Parkinson’s disease, the response to a levodopa dose may become shorter or less predictable. Patients can alternate between “on” periods, when movement is improved, and “off” periods, when symptoms return. An added dopamine agonist can reduce daily off time and sometimes permit a reduction in levodopa exposure. Dyskinesia can nevertheless increase when overall dopaminergic stimulation rises. This reflects the combined regimen rather than a simple opposition between levodopa and agonists.\n\nApomorphine has a particular role in this setting. Intermittent subcutaneous treatment can reverse selected off episodes, while continuous infusion is used for persistent motor fluctuations in some patients. Rotigotine and extended-release oral agonists provide other ways to extend dopaminergic stimulation. None of these methods reliably corrects every motor problem. Balance impairment, freezing of gait, speech changes, and other features may become only partly responsive—or unresponsive—to dopaminergic treatment.\n\nDopamine agonists also have effects beyond movement. Some studies have reported improvement in depressive symptoms or particular nonmotor symptoms, but such findings do not make the class a general treatment for depression or other psychiatric conditions. Conversely, cognitive impairment, hallucinations, autonomic dysfunction, and vulnerability to sleepiness can constrain their use. The benefit–risk balance differs substantially between a younger person with uncomplicated motor symptoms and an older person with dementia or recurrent falls.\n\nClinical improvement should be distinguished from disease modification. Dopamine agonists compensate for deficient signaling; they have not been established to halt neuronal degeneration. Imaging findings or reduced need for another medicine are not sufficient by themselves to demonstrate neuroprotection. Trials designed to examine progression must account for persistent symptomatic effects, treatment changes, and the imperfect relationship between imaging markers and neuronal survival."
    },
    {
      "heading": "Prolactin disorders and pituitary disease",
      "text": "Prolactin is a pituitary hormone involved principally in lactation and reproductive physiology. Excess secretion, termed hyperprolactinemia, can suppress gonadal function and produce menstrual disturbance, infertility, reduced libido, or galactorrhea. Prolonged sex-hormone deficiency can contribute to reduced bone density. Causes include prolactin-secreting tumors, certain medicines, hypothyroidism, and interruption of the normal hypothalamic inhibition of prolactin release.\n\nA prolactinoma is a pituitary tumor that secretes prolactin. Dopamine agonists are unusual among endocrine medicines because they can both correct hormone excess and shrink the causative tumor. D2-receptor activation inhibits prolactin secretion, reduces prolactin synthesis, and can restrain lactotroph growth. A reduction in tumor volume may relieve pressure on adjacent structures, including the optic pathways in larger tumors. The degree and speed of response vary, and prolactin concentration and tumor size do not always change in parallel.\n\nCabergoline is generally favored in contemporary prolactinoma practice because it is effective and often better tolerated than bromocriptine. Bromocriptine remains an important alternative and has a long history of clinical use, including extensive experience with exposure around conception. Quinagolide is another option in some countries. Responses are assessed through biochemical measurements, symptoms, and, when relevant, magnetic resonance imaging and visual assessment. These endpoints capture different aspects of disease rather than serving as interchangeable measures.\n\nSome prolactinomas show incomplete biochemical or structural responses despite substantial drug exposure. Definitions of resistance vary across studies and specialist guidance, often incorporating failure to normalize prolactin or achieve a specified reduction in tumor size. Treatment resistance is distinct from intolerance, in which adverse reactions prevent adequate exposure. Surgery and, less commonly, radiation-based treatment have roles in particular clinical circumstances, including selected resistant or compressive tumors.\n\nPregnancy introduces a separate physiological context. Prolactin rises normally during pregnancy, and pituitary tissue can enlarge. Restored ovulation after successful treatment can make conception possible even before menstrual cycles appear fully regular. The relevance of continued drug exposure depends on tumor characteristics and other clinical factors; practices differ between small, confined tumors and larger tumors near the optic apparatus. Pregnancy outcomes cannot be inferred from prolactin measurements alone.\n\nDopamine agonists also suppress lactation, but regulatory acceptance of this use differs between drugs and countries. Serious postpartum vascular and neurological reactions have shaped restrictions on bromocriptine for routine lactation suppression. In acromegaly, cabergoline can reduce growth-hormone-related biochemical activity in some patients, particularly those with relatively modest elevations, but its effect is less consistent than its action in prolactinomas. These endocrine uses involve different doses, endpoints, and risk assessments from Parkinson’s treatment."
    },
    {
      "heading": "Restless legs syndrome and other indications",
      "text": "Restless legs syndrome is characterized by an urge to move the legs, typically accompanied by uncomfortable sensations, that emerges or worsens during rest, improves with movement, and is most prominent in the evening or at night. Dopamine agonists can reduce these symptoms and associated periodic limb movements during sleep. Pramipexole, ropinirole, and rotigotine have been licensed for this indication in various jurisdictions, generally at lower exposures than those used in Parkinson’s disease.\n\nThe major limitation of long-term dopaminergic treatment in this condition is augmentation. This is a treatment-associated worsening in which symptoms begin earlier in the day, appear more rapidly during rest, become more intense, or spread to other body regions. It differs from simple loss of efficacy, ordinary disease progression, and rebound symptoms as a dose wears off. A short-term response to a higher dose does not exclude augmentation and may complicate its subsequent course.\n\nRecognition of augmentation has changed the position of dopamine agonists in restless legs syndrome. Contemporary guidance gives greater weight to long-term outcomes rather than symptom reduction over a few weeks. The American Academy of Sleep Medicine’s 2025 clinical practice guideline suggested against the standard use of pramipexole, ropinirole, and rotigotine in adults with the disorder, reflecting the balance between short-term benefit and long-term augmentation risk. This does not mean that the drugs lack efficacy; it distinguishes efficacy from preferred routine use.\n\nOther applications depend on pharmacology outside the motor system. A quick-release formulation of bromocriptine is approved in the United States as an adjunct to diet and exercise for adults with type 2 diabetes. Its glucose-lowering mechanism is not fully established. Proposed explanations involve central dopaminergic effects on circadian and metabolic regulation, with downstream changes in hepatic glucose production and insulin sensitivity. This indication cannot be generalized to other bromocriptine formulations or to all dopamine agonists.\n\nFenoldopam illustrates a peripheral vascular application. D1-receptor activation relaxes arterial smooth muscle and increases blood flow in several vascular beds, including the renal circulation. Its short action permits intravenous titration in severe hypertension. Increased renal blood flow or urine output, however, does not by itself establish prevention of acute kidney injury or improvement in survival. Physiological effects and patient-important outcomes require separate evidence.\n\nDopamine agonists have also been investigated for diverse neurological, psychiatric, and endocrine conditions. Such studies do not establish a class-wide indication. Differences in receptor targets, disease mechanisms, trial size, and outcome measurement are substantial. A positive finding for one compound in a defined population cannot be assumed to apply to another compound or to routine treatment outside that setting."
    },
    {
      "heading": "General adverse effects and organ-specific toxicity",
      "text": "Common adverse effects include nausea, vomiting, light-headedness, and orthostatic hypotension, in which blood pressure falls on standing. Nausea partly reflects stimulation of dopamine-sensitive pathways involved in emesis, including structures with relatively limited blood–brain barrier protection. Blood-pressure effects involve autonomic and vascular mechanisms and may be compounded by Parkinson’s disease itself. These reactions are often most evident when exposure is initiated or increased.\n\nSomnolence is another important class effect. Some patients experience episodes of falling asleep during activities without recognizing strong preceding sleepiness. Such events have been reported with several dopamine agonists and are not confined to a single formulation. Sleep disorders, other sedating medicines, and the underlying neurological disease complicate attribution. The clinical significance extends beyond discomfort because impaired alertness can affect driving and other activities requiring sustained attention.\n\nHallucinations, confusion, and other psychotic symptoms can occur, especially in patients with cognitive impairment or advanced Parkinson’s disease. Visual hallucinations are particularly recognized in this setting. The underlying disease, infection, metabolic disturbance, and other medicines may also contribute, so a temporal association with an agonist does not establish a single cause. Peripheral edema is another recognized reaction; its mechanism is incompletely understood and differs from the mechanisms responsible for every other cause of leg swelling.\n\nErgot-associated fibrosis is a more drug-specific problem. Pergolide and cabergoline, especially at the higher cumulative exposures historically used in Parkinson’s disease, have been associated with cardiac valve abnormalities. Activation of serotonin 5-HT2B receptors on valve-associated cells is an important mechanism, promoting cellular proliferation and extracellular matrix deposition. Pleural, pulmonary, pericardial, and retroperitoneal fibrosis have also been reported with certain ergot-derived agents. These effects are not considered a uniform property of non-ergot dopamine agonists.\n\nThe risk context differs between neurological and endocrine treatment. Cabergoline exposure in prolactinoma treatment is usually substantially lower than in historical Parkinson’s regimens. Consequently, findings from high-dose neurological use cannot be transferred directly to every endocrine patient. Studies and guidelines have examined cumulative exposure and the role of echocardiographic surveillance, but protocols differ. A mild valve finding on imaging is also not necessarily equivalent to clinically important drug-associated valvulopathy.\n\nDrug interactions can alter both efficacy and toxicity. Dopamine receptor antagonists may counteract therapeutic effects, while other hypotensive or sedating medicines may intensify adverse reactions. Apomorphine has a particularly important interaction with 5-HT3-antagonist antiemetics, including ondansetron: concomitant use is contraindicated in product labeling because profound hypotension and loss of consciousness have been reported. Such interactions show why treatment-related nausea cannot be considered independently of the pharmacology of the medicine used to address it."
    },
    {
      "heading": "Impulse-control disorders and withdrawal phenomena",
      "text": "Dopamine agonists can produce clinically significant changes in reward-seeking behavior. Recognized impulse-control disorders include pathological gambling, compulsive buying, compulsive sexual behavior, and compulsive or binge eating. Repetitive, purposeless activities known as punding may also occur during dopaminergic treatment, although their associations across drug regimens are not identical. These behaviors can cause financial, interpersonal, and occupational harm without appearing as a conventional physical adverse reaction.\n\nThe association is particularly well documented in Parkinson’s disease. In a large cross-sectional study published in 2010 involving 3,090 treated patients, an impulse-control disorder was identified in 13.6% overall. The proportion was higher among those receiving a dopamine agonist than among those not receiving one. Such figures describe a particular study population and assessment method, not a universal incidence rate. Estimates vary with exposure duration, definitions, ascertainment, and patient characteristics.\n\nMesolimbic dopamine pathways, which contribute to motivation and reinforcement learning, provide a plausible biological basis. D3-preferring activity has received particular attention because of receptor distribution in reward-related circuits. Nevertheless, the mechanisms are not reducible to one receptor subtype. Predisposing characteristics, disease-related changes, dose, concurrent therapy, and environmental opportunities all influence observed behavior. No routinely used test can identify every person who will develop these complications.\n\nBehavioral effects are not restricted to Parkinson’s disease. They have also been reported with the lower-dose regimens used in restless legs syndrome and prolactin disorders. The frequency and risk profile in these populations are less directly comparable because studies differ in design and underlying disease. The absence of motor disease does not eliminate the relevance of central dopamine signaling, while the presence of an adverse behavior does not establish that every aspect of it is medication-induced.\n\nReduction or discontinuation can itself produce a distinct problem, termed dopamine agonist withdrawal syndrome. Reported features include anxiety, panic, depressed mood, dysphoria, pain, fatigue, sweating, and drug craving. Symptoms may be severe and do not necessarily respond to substitution with levodopa. The syndrome has been associated especially with a history of impulse-control disorders and substantial agonist exposure, although these factors do not explain every case.\n\nWithdrawal phenomena must be distinguished from recurrence of the treated disorder. Increased rigidity after treatment reduction, renewed restless legs symptoms, and rising prolactin are different outcomes from a withdrawal syndrome, even when they occur together. Abrupt disruption of dopaminergic therapy in Parkinson’s disease can also contribute to a rare, severe syndrome involving marked rigidity, fever, and autonomic instability. Clinical interpretation therefore depends on the pattern and timing of symptoms, not simply on whether a drug has recently been stopped."
    },
    {
      "heading": "Historical development and evaluation of evidence",
      "text": "The development of dopamine agonists followed the recognition of dopamine as a neurotransmitter rather than merely an intermediate in catecholamine synthesis. Arvid Carlsson’s experiments in the late 1950s helped establish its role in movement, and work by Oleh Hornykiewicz and colleagues identified severe striatal dopamine depletion in Parkinson’s disease around 1960. These findings supplied the biological rationale for replacing deficient dopamine signaling. Carlsson later shared the 2000 Nobel Prize in Physiology or Medicine for discoveries concerning nervous-system signal transduction.\n\nLevodopa transformed Parkinson’s treatment during the 1960s, but its limitations stimulated interest in drugs that could activate dopamine receptors directly. Bromocriptine entered clinical use in the 1970s and linked two major applications of dopamine pharmacology: movement disorders and prolactin suppression. Subsequent decades brought additional ergot derivatives, then non-ergot agents with different receptor profiles and more convenient delivery systems. Pramipexole and ropinirole entered major markets in the 1990s; transdermal and infusion approaches expanded the options for sustained stimulation.\n\nApomorphine has a longer history than these modern treatment programs. Its emetic and behavioral effects were investigated well before contemporary receptor classification, but practical antiparkinsonian use depended on developments in formulation, delivery, and management of adverse effects. Its trajectory illustrates a recurring distinction in drug development: recognizing pharmacological activity is not the same as establishing a workable long-term treatment. Similar considerations apply to oral extended-release preparations and continuous delivery devices.\n\nEvidence differs by indication and outcome. In Parkinson’s disease, a randomized controlled trial may assess motor scores, daily off time, dyskinesia, treatment discontinuation, or health-related quality of life. In prolactinomas, biochemical normalization and tumor shrinkage are central endpoints. In restless legs syndrome, short-term symptom scores must be considered alongside augmentation developing over months or years. No single outcome establishes superiority across all these settings.\n\nSeveral important harms became clearer through observational research and pharmacovigilance rather than initial efficacy trials. Cardiac valve disease associated with particular ergot derivatives and compulsive behaviors associated with dopaminergic therapy required large populations, careful clinical observation, and attention to cumulative exposure. A cohort study can capture longer-term patterns, but confounding by disease severity, treatment selection, and concurrent medicines remains important. Randomized and observational evidence answer complementary questions.\n\nResearch on receptor-selective compounds, signaling pathways, and continuous delivery continues to test whether therapeutic effects can be separated more effectively from adverse reactions. Proposed neuroprotective effects remain distinct from established symptomatic benefits. Demonstrating a change in a biomarker or a laboratory signaling pathway does not establish improved daily function, slower clinical progression, or greater survival; those claims require appropriately designed human studies with outcomes suited to the indication."
    }
  ],
  "links": [
    "dopamine",
    "parkinsons-disease",
    "hypothalamus",
    "opioid",
    "hypertension",
    "pharmacokinetics",
    "blood-brain-barrier",
    "kidney",
    "pharmacodynamics",
    "depression",
    "dementia",
    "hormone",
    "magnetic-resonance-imaging",
    "surgery",
    "pregnancy",
    "type-two-diabetes",
    "circadian-rhythm",
    "nausea",
    "edema",
    "impulse-control-disorder",
    "pain",
    "nobel-prize-in-physiology-or-medicine",
    "drug-development",
    "randomized-controlled-trial",
    "health-related-quality-of-life",
    "pharmacovigilance",
    "cohort-study",
    "biomarker"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}